Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

This work was primarily funded by the European Research Council, the Swiss National Science Foundation, the Swiss Cancer League, and the Forschungsförderung of the Kantonsspital St. Gallen.